AXINAB AXirubicin-e® IN Adjuvant Breast CancerNon - interventional study on the efficacy and tolerability of epirubicin in the treatment of breast cancer - AXINAB

The documentation of the general condition serves as a helpful tool for assessing the ability to undergo therapy and acts as a predictor for the prognosis of survival time. General condition can also be used as an informative outcome measure in treatment planning, especially in advanced stages and in multimodal therapies (cf. Moinpour 1997). The analysis of the present study recommends the use of a single classification system for the assessment of general conditions. Due to the sharper scaling, the Karnofsky scale has advantages over the ECOG scale. A further advantage of using a single classification system is the better informative value due to the use of more homogeneous data material. Concerning anthracycline-induced cardiotoxicity, the preliminary results show that a shortened duration of application may be associated with an increased risk. This emphasizes the importance of precise monitoring and careful dosing, while future research requires full consideration of individual patient characteristics. The preliminary results suggest that dose modifications during anthracycline-containing therapy are often due to side effects and physician decisions, and further analysis should clarify the long-term effects and possible adjustments in treatment protocols. Combination therapies are preferred. In conclusion, the results underline the need for individualized and patient-centered therapy to overcome potential barriers to treatment adherence and optimize treatment outcomes. In the case of treatment discontinuations due to administrative reasons, it becomes clear that a patient-centered approach is also crucial in overcoming organizational hurdles to ensure continuous and effective treatment.